Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
November 11, 2024 05:00 ET
|
Tectonic Therapeutic
Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow...
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024 16:01 ET
|
Tectonic Therapeutic
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early Q2’2025First subject dosed with TX000045 (“TX45”) in APEX...
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
October 22, 2024 16:01 ET
|
Tectonic Therapeutic
WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of...
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
September 19, 2024 16:01 ET
|
Tectonic Therapeutic
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at...
Tectonic Therapeutic to Participate in September Investor Conferences
August 20, 2024 16:01 ET
|
Tectonic Therapeutic
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
August 14, 2024 16:01 ET
|
Tectonic Therapeutic
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
July 30, 2024 16:01 ET
|
Tectonic Therapeutic
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019
February 01, 2019 07:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and...
AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis
January 18, 2019 07:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy...
AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019
January 17, 2019 07:00 ET
|
AVROBIO, Inc.
CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related...